How to fix a broken market in antibiotics
The drugs don't work - and neither does the market, when it comes to antibiotics. When sophisticated bugs that medicines used to kill within days start to fight back and...
All Stories
Cameron enlists ex-Goldman economist in global superbug fight
LONDON (Reuters) - Prime Minister David Cameron called on Wednesday for global action to tackle the threat of drug-resistant superbugs and said Britain planned to take a leading role in...
French biotech Cellectis surges as Pfizer signs cancer drug deal
By Ben Hirschler (Reuters) - U.S. drugmaker Pfizer, which failed last month in a $118 billion bid to buy AstraZeneca, said on Wednesday it had signed a deal with French...
Drug-linked payouts: complex fix for Pfizer’s next Astra bid?
By Ben Hirschler and Anjuli Davies LONDON (Reuters) - The world's biggest would-be drugs merger hit a wall last month but speculation about smart ways that Pfizer could yet seal...
Top scientists warn WHO not to stub out e-cigarettes
By Ben Hirschler LONDON (Reuters) - A group of 53 leading scientists has warned the World Health Organization not to classify e-cigarettes as tobacco products, arguing that doing so would...
Pfizer walks away from $118 billion AstraZeneca takeover fight
By Ben Hirschler and Bill Berkrot LONDON/NEW YORK (Reuters) - Pfizer abandoned its attempt to buy AstraZeneca for nearly 70 billion pounds ($118 billion) on Monday as a deadline approached...
UK labs play shrinking role in AstraZeneca drug portfolio
LONDON (Reuters) - How British is AstraZeneca? With a French chief executive, Swedish chairman, 40 percent of its sales in the United States and 87 percent of its staff overseas,...
UK finance minister ready for ‘hard negotiation’ with Pfizer
LONDON (Reuters) - Britain is ready for "hard negotiation" to ensure Pfizer sticks to specific promises on jobs and science under the U.S. drugmaker's proposed takeover of AstraZeneca, its finance...
Pfizer under fire in Europe, U.S. as it weighs next Astra move
LONDON (Reuters) - U.S. drugmaker Pfizer is under fire on both sides of the Atlantic as it weighs its next move to buy British rival AstraZeneca , which could be...
In AstraZeneca fight, valuing drugs as much art as science
LONDON (Reuters) - Ten-year sales forecasts from AstraZeneca - a central plank of its defense against a $106 billion bid approach from Pfizer - underscore how valuing drugs is an...